http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Mar 2026 09:16:15 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Psyence+BioMed+exports+psilocybin+to+Australia+for+Phase+IIb+trial/26097913.html <p>Psyence Biomedical Ltd. (NASDAQ: PBM) announced the export of GMP-manufactured natural psilocybin product NPX-5 to Australia for its ongoing Phase IIb clinical trial. The shipment includes 1mg and 5mg capsules manufactured at the Psyence Labs Ltd. facility.</p><p>The exported product will be used in a double-blind, randomized, multi-center study evaluating natural psilocybin for treating Adjustment Disorder in cancer patients receiving palliative care. The trial is enrolling 87 participants across multiple Australian sites, including Melbourne and Perth.</p><p>Patient dosing began in late 2025, with newly enrolled patients receiving NPX-5. The company states it is conducting the only Phase IIb clinical trial using natural http://www.streetinsider.com/Corporate+News/Psyence+BioMed+exports+psilocybin+to+Australia+for+Phase+IIb+trial/26097913.html Tue, 03 Mar 2026 09:16:15 -0500 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Export+of+GMP-Manufactured+Natural+Psilocybin+%28NPX-5%29+to+Australia+for+Ongoing+Phase+IIb+Clinical+Trial/26097902.html <p align="justify">NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production facility, supporting pharmaceutical-grade psychedelic development.</p> <p align="justify">The shipment represents an operational achievement for both Psyence BioMed and PsyLabs, reinforcing their shared commitment to establishing a regulated global supply chain for nature-derived psychedelic therapeutics.</p> http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Export+of+GMP-Manufactured+Natural+Psilocybin+%28NPX-5%29+to+Australia+for+Ongoing+Phase+IIb+Clinical+Trial/26097902.html Tue, 03 Mar 2026 09:15:00 -0500 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Export+of+GMP-Manufactured+Natural+Psilocybin+%28NPX-5%29+to+Australia+for+Ongoing+Phase+IIb+Clinical+Trial/26097902.html <p align="justify">NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the successful export of fully GMP-compliant manufactured psilocybin product NPX-5 (1mg and 5mg capsules) to Australia. The product was manufactured at the Psyence Labs Ltd. (“PsyLabs”) GMP-controlled production facility, supporting pharmaceutical-grade psychedelic development.</p> <p align="justify">The shipment represents an operational achievement for both Psyence BioMed and PsyLabs, reinforcing their shared commitment to establishing a regulated global supply chain for nature-derived psychedelic therapeutics.</p> http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Export+of+GMP-Manufactured+Natural+Psilocybin+%28NPX-5%29+to+Australia+for+Ongoing+Phase+IIb+Clinical+Trial/26097902.html Tue, 03 Mar 2026 09:15:00 -0500 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Mar+02/26086869.html si-local-file:///var/storage/secattach/20260302/26086869.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Mar+02/26086869.html Mon, 02 Mar 2026 07:08:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Mar+02/26086869.html si-local-file:///var/storage/secattach/20260302/26086869.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Mar+02/26086869.html Mon, 02 Mar 2026 07:08:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26037292.html si-local-file:///var/storage/secattach/20260220/26037292.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26037292.html Fri, 20 Feb 2026 17:25:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26037292.html si-local-file:///var/storage/secattach/20260220/26037292.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26037292.html Fri, 20 Feb 2026 17:25:00 -0500 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html <p align="justify">NEW YORK, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that Psyence Labs Ltd., a leading developer and manufacturer of pharmaceutical-grade psychedelic compounds (&quot;<strong>PsyLabs</strong>&quot;) has exercised its rights under a previously disclosed put option agreement (the &quot;<strong>Put Option Agreement</strong>&quot;), pursuant to which Psyence BioMed will make an equity investment in PsyLabs at a fair market value determined in accordance with the terms of the Put Option Agreement.</p> <p align="justify">The Put Option Agreement http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Exercise+of+Put+Option+by+PsyLabs+and+Strategic+Equity+Investment/26037228.html Fri, 20 Feb 2026 17:20:00 -0500 A.32665314 O.22266999 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Weiner+Jeffrey+David/26027978.html si-local-file:///var/storage/secattach/20260219/26027978.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Weiner+Jeffrey+David/26027978.html Thu, 19 Feb 2026 11:20:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Weiner+Jeffrey+David/26027978.html si-local-file:///var/storage/secattach/20260219/26027978.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PSYENCE+BIOMEDICAL+LTD.++++++++++++++++Filed+by%3A+Weiner+Jeffrey+David/26027978.html Thu, 19 Feb 2026 11:20:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26025922.html si-local-file:///var/storage/secattach/20260219/26025922.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26025922.html Thu, 19 Feb 2026 07:20:00 -0500 O.65258044 PBM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26025922.html si-local-file:///var/storage/secattach/20260219/26025922.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++PSYENCE+BIOMEDICAL+LTD.+++For%3A+Feb+19/26025922.html Thu, 19 Feb 2026 07:20:00 -0500 O.65258044 PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html <p align="justify">NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “<strong>Meeting</strong>”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “<strong>Board</strong>”).</p> <p align="justify">All director http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html Tue, 17 Feb 2026 09:15:00 -0500 PBM PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html <p align="justify">NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “<strong>Meeting</strong>”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “<strong>Board</strong>”).</p> <p align="justify">All director http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html Tue, 17 Feb 2026 09:15:00 -0500 PBM PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html <p align="justify">NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “<strong>Meeting</strong>”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “<strong>Board</strong>”).</p> <p align="justify">All director http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html Tue, 17 Feb 2026 09:15:00 -0500 PBM PBM http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html <p align="justify">NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the “<strong>Meeting</strong>”), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the “<strong>Board</strong>”).</p> <p align="justify">All director http://www.streetinsider.com/Globe+Newswire/Psyence+BioMed+Announces+Results+of+Annual+and+Special+Meeting+of+Shareholders/26007931.html Tue, 17 Feb 2026 09:15:00 -0500 PBM PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Approves+Put+Option+Agreement+with+PsyLabs+to+Secure+Strategic+Supply+and+Strengthen+Commercialization+Pathway/26002490.html <p><strong>The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world&apos;s most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds</strong></p><p align="justify">NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its board of directors has ratified the entry into a put option agreement (the “<strong>Put Option Agreement</strong>”) with PsyLabs, a leading developer and http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Approves+Put+Option+Agreement+with+PsyLabs+to+Secure+Strategic+Supply+and+Strengthen+Commercialization+Pathway/26002490.html Fri, 13 Feb 2026 18:30:00 -0500 PBM PBM http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Approves+Put+Option+Agreement+with+PsyLabs+to+Secure+Strategic+Supply+and+Strengthen+Commercialization+Pathway/26002490.html <p><strong>The Put Option Agreement positions Psyence BioMed for potential significant future equity participation in one of the world&apos;s most advanced psychedelic pharmaceutical grade manufacturers, thereby securing predictable and reliable supply of pharmaceutical grade psychedelics, as the pathway to commercialization unfolds</strong></p><p align="justify">NEW YORK, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“<strong>Psyence BioMed</strong>” or the “<strong>Company</strong>”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its board of directors has ratified the entry into a put option agreement (the “<strong>Put Option Agreement</strong>”) with PsyLabs, a leading developer and http://www.streetinsider.com/Press+Releases/Psyence+BioMed+Approves+Put+Option+Agreement+with+PsyLabs+to+Secure+Strategic+Supply+and+Strengthen+Commercialization+Pathway/26002490.html Fri, 13 Feb 2026 18:30:00 -0500 PBM PBM